Systemic Side Effects of Ophthalmic Drops

Clinical Pediatrics

Volumn 43, Issue 1, 2004, Pages 99-101

  Levy, Yair ^a,b   Zadok, David ^b,c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; DORZOLAMIDE; EYE DROPS; LATANOPROST; TIMOLOL MALEATE;

ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; DRUG APPROVAL; DRUG INDICATION; DRUG METABOLISM; FEMALE; GLAUCOMA; HIGH RISK POPULATION; HUMAN; INFANT; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; PRESCHOOL CHILD; RISK ASSESSMENT; SOMNOLENCE; SYSTEMIC DISEASE;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; CHILD, PRESCHOOL; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; INFANT; MALE; OPHTHALMIC SOLUTIONS; QUINOXALINES;

EID: 1642458236     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280404300114     Document Type: Article

References (12)

1. Palmer EA. How safe are ocular drugs in pediatrics? Ophthalmology. 1986;93:1038-1040.
2. Juzych MS, Robin AL, Novack GD. Alpha-2 agonists in glaucoma therapy. In Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD (eds): Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven, 1997:247-254.
3. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:199-248.
4. Stein B, Volans GN. Dixarit overdose: the problem of attractive tablets. BMJ. 1978;2:667-668.
5. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-852.
6. Reid JL. Alpha-adrenergic receptors and blood pressure control. Am J Cardiol. 1986;57:6E-12E.
7. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5:281-284.
8. Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138:441-443.
9. Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255-256.
10. Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma [letter]. Eur J Pediatr. 1999;158:685.
11. Walters G, Taylor RH. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma [letter]. Eye. 1999;13:797-798.
12. Passo MS, Palmer EA, vanBuskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.